CD274 and small cell lung carcinoma: Indeed, representing the most significant therapeutic novelties for decades, immunotherapeutic targeting of anti-programmed death-ligand 1 (PD-L1) has been recently included into the treatment guidelines for extensive-stage SCLC patients.15